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Recent molecular genetic studies have revealed that
two major types of genomic instabilities, chromo-
somal instability and microsatellite instability, exist
in the colorectal carcinomas. To clarify the relation-
ship between chromosomal abnormalities and mis-
match repair gene defects in colorectal carcinomas,
we performed a chromosomal analysis on 39 colorec-
tal carcinomas with high-microsatellite instability
(MSI-H) and compared the results obtained with those
of 20 right-sided microsatellite-stable (MSS) colorectal
carcinomas. Chromosomal imbalances (CIs) in MSS
colorectal carcinomas were more frequent than in
MSI-H colon carcinomas by comparative genomic hy-
bridization analysis (70% versus 31%, P 0.004). The
CI patterns of MSI-H and MSS carcinomas were differ-
ent. Frequent CIs in MSI-H colon carcinomas were
gains of 4q (15%) and 8q (8%), and losses of 9q (21%),
1p (18%), and 11q (18%). In contrast, frequent CIs in
right-sided MSS colon carcinomas were gains of 8q
(50%), 13q (35%), and 20q (25%), and losses of 18q
(55%), 15q (35%), and 17p (30%). We compared the
mutation status of 45 target genes and CIs in our
MSI-H tumors. Among these 45 target genes, mutation
of hRAD50 , a member of the DNA repair genes, and
FLJ11383 were significantly related to MSI-H colorec-
tal carcinomas with CIs (P  0.01 and P  0.02,
respectively). Our findings indicate that unique CIs
were present in a subset of MSI-H colorectal carcino-
mas and that these CIs are related to the mutation of
several target genes, especially of hRAD50. (Am J
Pathol 2003, 163:1429–1436)
It is widely accepted that the molecular genetics of hu-
man cancers can be used to categorize colorectal car-
cinomas into two major types of genomic instabilities,
chromosomal instability (CIN) and microsatellite instabil-
ity (MSI).1 The majority of colorectal carcinomas are cat-
egorized into the CIN pathway, which is characterized by
a high frequency of allelic losses, deletions, and/or mu-
tations of tumor suppressor genes such as APC and p53,
and abnormal tumor DNA.2 Aneuploidy in CIN phenotype
tumors had been demonstrated in colorectal cancer cell
lines3 and tumor tissues.4 Although CIN is a common
finding in colorectal carcinomas, the mechanism of CIN
has not been clearly elucidated. Defects in DNA replica-
tion check point genes and many other genes increase
the rate of genome rearrangement and it is suggested to
be associated with CIN.5–8
The other pathway, namely the MSI pathway, begins
with the inactivation of one of a group of genes respon-
sible for DNA nucleotide mismatch repair, which leads to
extensive mutations in both repetitive and nonrepetitive
DNA sequences with low frequencies of allelic losses and
rare alterations of tumor DNA content.9,10 The mecha-
nism of tumorigenesis in high-microsatellite instability
(MSI-H) tumors is thought to involve frameshift mutations
of microsatellite repeats within coding regions of the af-
fected target genes, and the inactivation of these target
genes is believed to directly contribute to tumor devel-
opment and progression.
Although these two distinct major genetic pathways of
genetic instabilities are widely accepted, some tumors
reveal different genetic pathways; ie, some tumors show
both types of genomic instabilities and some tumors do
not show any of these two instabilities.11–13 To clarify the
relationship between these two genetic instabilities in
colorectal carcinomas, we analyzed chromosomal imbal-
ances (CIs) in 39 MSI-H colorectal carcinomas and com-




Thirty-nine cases confirmed as MSI-H colorectal carcino-
mas, and 20 cases of right-sided MSS colorectal carci-
nomas were included in this study. In each case, grossly
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normal mucosa remote from the tumor was included as a
control. All cases were identified consecutively at the
Gastrointestinal Tumor Working Group Tissue Bank at
Yonsei University Medical Center (Seoul, Korea) between
December 1996 and November 1999. Cases included in
this study were sporadic tumors without relevant family
history or clinical evidence of familial adenomatous pol-
yposis or hereditary nonpolyposis colorectal cancer.
DNAs were extracted from fresh-frozen tissues. Tumor
specimens were microdissected on a cryostat and frac-
tionated to enrich the tumor cell population as described
previously.14,15
Screening of Microsatellite Instability
DNAs from tumors and normal mucosae were polymer-
ase chain reaction (PCR) amplified at six microsatellite
loci to evaluate the MSI. These markers included the
recommended panel of five markers proposed at the
National Cancer Institute Collaboratory Meeting and MSI
in colorectal cancer16 plus BAT40. PCR reactions were
performed in a mixture of 20 l containing 1.5 mmol/L
MgCl2; 20 pmol of primer; 0.2 mmol/L each of dATP,
dGTP, and dTTP; 5 mol/L dCTP; 1 Ci of [-32P]-dCTP
(3000 Ci/mmol; DuPont New England Nuclear, Boston,
MA); 50 ng of sample DNA; 1 PCR buffer; and 1.25 U of
Taq polymerase (Life Technologies, Inc., Grand Island,
NY). After denaturation at 95°C for 5 minutes, DNA am-
plification was performed for 25 to 30 cycles consisting of
denaturation at 95°C for 30 seconds, primer annealing at
55 to 60°C for 30 seconds, and elongation at 72°C for 15
seconds. PCR products were separated in 6% polyacryl-
amide gels containing 5.6 mol/L of urea, followed by
autoradiography. MSI was determined by the mobility
shift of products from PCR. In tumors with MSI, additional
bands were found in the normal allele regions. MSI in
three or more markers of which more than two mononu-
cleotide repeat markers were included was classified as
MSI-H; and those showing no instability were classified
as MSS (Figure 1A). Methylation analysis of hMLH1 and
expression analysis of hMLH1 and hMSH2 were per-
formed as described previously.17,18
Comparative Genomic Hybridization (CGH) and
Digital Image Analysis
Genomic DNA samples from tumors were labeled with
Spectrum Green dUTP (Vysis Inc., Downers Grove, IL),
and normal reference genomic DNA was labeled with
Spectrum Red dUTP (Vysis) using the nick translation
technique. Labeled tumor and reference DNA (200 to 400
ng), and 10 g of unlabeled human Cot-1 DNA (Vysis)
were dissolved in 10 l of hybridization buffer (50% for-
mamide, 10% dextran sulfate, and 2 standard saline
citrate) and denatured at 72°C for 2 minutes. Hybridiza-
tion was performed at 37°C on denatured normal meta-
phase spreads. After hybridization for 3 days, the slides
were washed and counterstained with 4,6-diamidino-2-
phenylindole dihydrochloride in anti-fade solution. CGHs
were analyzed using an Olympus fluorescent microscope
and the Cytovision image analysis system (Applied Im-
aging; Times Square, Newcastle upon Tyne, UK). Three
digital images (4,6-diamidino-2-phenylindole dihydro-
chloride, Spectrum Green, Spectrum Red) were acquired
from 10 to 20 metaphases in each hybridization. Normal
male DNA and DNA from tumor cell lines with known
aberrations were used as DNA test controls. Green-to-
red intensity ratio profiles were calculated for each chro-
mosome and threshold values defining gains and losses
were set at 1.25 and 0.75, respectively (Figure 1, B and
C). Only the chromosomal losses and gains were ana-
lyzed because reciprocal translocation cannot be differ-
entiated by CGH analysis. We regarded tumors as CIs
when any chromosomal losses or gains were present in
the tumors. The CIs of five chromosomal arms were val-
idated by PCR-loss of heterozygosity (LOH) analysis us-
ing seven microsatellite markers (D9S195, D16S521,
D17S578, D17S250, D18S58, D18S57, DCC).
Detection of Frameshift Mutation
We chose the 45 target genes of MSI-H carcinomas
based on the reported frequency of frameshift mutations
and their functions. Genes with mutation frequencies of
more than 30% (24 genes), genes containing more than
10 mononucleotide repeats (16 genes), and genes that
are reported to be involved in the suppression of genome
instability (5 genes)14,15,19–22 were selected. The inci-
dence of frameshift mutations had been previously re-
ported in 38 of 45 genes in our 39 MSI-H colorectal
carcinomas.14,15,19 DNA preparation, the MSI status of all
cases, and frameshift mutations of the 38 target genes
have been previously reported.14,15,19 The analyzed tar-
get genes were ABCF1, ACVRII, AIM2, ATR, BAX, BLM,
BRCA1, BRCA2, Caspase 5, CHD2, DKFZp564C2478,
FLJ11186, FLJ11222, FLJ11383, FLJ11712, FLJ13615,
FLJ20139, FLJ20333, GART, GRB-14, hMSH3, hMSH6,
hRAD50, KIAA1052, KIAA1096, KIAA1268, KIAA1470,
MAC30, MARCKS, MBD4, NADH-UOB, OGT, PRKDC,
PRKWNK1, RFC3, SEC63, SLC24AI, SPINK5, SYCP1,
TAF1B, TCF4, TCF6L1, TGF- RII, UVRAG, and WISP3.
All PCR products of these genes showed one band from
the normal DNA, whereas monoallelic or biallelic muta-
tions were present in some MSI-H tumors (Figure 2).
Statistical Analysis
Clinicopathological variables and the presence of frame-
shift mutations of the target genes were cross-tabulated
with the source (MSI-H colorectal carcinomas with CIs
and those without CIs), and the significance of associa-
tion was determined by using the Pearson’s chi-square
test or Fisher’s exact test. The mean number and mean
incidence of frameshift mutations of target genes in
MSI-H colorectal carcinomas with and without CIs were
determined using Student’s t-test. All calculations were
performed using the SPSS 10.0 for Windows statistical
software package (SPSS Inc., Chicago, IL).
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Figure 1. Examples of MSI, CGH, and PCR-LOH analysis in MSI-H (case 17) and MSS (case 60) colorectal carcinoma with CIs. A: MSI analysis. Additional alleles
were found at six microsatellite markers in a MSI-H colorectal carcinoma and no changes were found in a MSS colorectal carcinoma. B: CGH analysis. CIs were
found in 9q, 16p, 17p, and 17q in MSI-H colorectal carcinoma (left) and 8q, 16p, 17p, 17q, and 18q in MSS colorectal carcinoma (right). C: Comparison of CGH
analysis and PCR-LOH. PCR-LOH analysis showed same allelic imbalance (arrow) in 17p and 18q in MSS colorectal carcinoma (right), whereas comparison was
not possible in MSI-H carcinoma because of shifted bands in 9q, 16p, 17p, 17q, and 18q (left).
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Results
CIs in MSI-H Colorectal Carcinomas
We found CIs in 12 (31%) of 39 MSI-H colorectal carci-
nomas by CGH analysis and the average number of CIs
in MSI-H carcinomas was 2.1. CIs showed a rather ran-
dom distribution over the chromosomes, although there
were more losses than gains (ratio of losses to gains,
5.9:1). Chromosomal arm imbalances did not exceed
25% in MSI-H tumors (Figure 3A). Most frequent CIs in
MSI-H tumors were gains of 4q (15%) and losses of 9q
(21%), 1p (18%), and 11q (18%).
Comparison of CIs in MSI-H and MSS
Colorectal Carcinomas
We compared the results of CIs of the 39 MSI-H colorec-
tal carcinomas to those of the 20 MSS colon carcinomas.
We found CIs in 14 (70%) of 20 MSS colon carcinomas
(Figure 3B). In addition to more frequent CIs in the MSS
tumors (31% versus 70%, P  0.004), the average num-
ber of CIs was significantly higher in the MSS carcinomas
(2.1 versus 4.4, P  0.04). Moreover, the MSS carcino-
mas showed distinct and different CIs from the MSI-H
carcinomas. Frequent changes in MSS carcinomas were
gains of 8q (50%), 13q (35%), and 20q (25%), and losses
of 18q (55%), 15q (35%), and 17p (30%). None of these
changes were included in the chromosomal arms show-
ing frequent changes in our 39 MSI-H colorectal carcino-
mas (Figure 3). CIs in all of the five chromosomal arms
were validated by seven microsatellite markers. The
PCR-LOH results were matched with all 20 MSS tumors,
however it could not be evaluated in most of the MSI-H
tumors because of frequent microsatellite instability in
these seven markers (Figure 1C).
Clinicopathological Characteristics Related to
CIs in MSI-H Colorectal Carcinomas
We analyzed the relationship between the incidence of
CIs and clinicopathological variables in our 39 MSI-H
colorectal carcinomas. No clinicopathological feature
was significantly associated with CIs in MSI-H carcino-
mas. Tumor stage, differentiation, mucin production, and
peritumoral lymphoid reaction were not related to the
chromosomal changes in MSI-H colorectal carcinomas.
Expression of mismatch repair proteins and methylation
of hMLH1 were not related to the chromosomal changes
in MSI-H colorectal carcinomas (Table 1).
Relationship between CIs and Target Gene
Mutations in MSI-H Colorectal Carcinomas
We analyzed the relationship between the incidence of
CIs and the incidence of frameshift mutations of the 45
target genes we analyzed previously.14,15,19 The mean
number of frameshift mutations of the 45 target genes
was 18.3 in the MSI-H carcinomas with CIs and 15.4 in
the MSI-H carcinomas without CIs (P  0.20). The mean
incidence of frameshift mutations of the 45 target genes
in MSI-H colorectal carcinomas with CIs was 41%, and in
MSI-H colorectal carcinomas without CIs was 34% (P 
Figure 2. Frameshift mutations of target genes in MSI-H and MSS colorectal
carcinomas. All of five MSI-H colorectal carcinomas showed shifted bands in
all three mononucleotide repeat microsatellite markers (BAT26, BAT25, and
BAT40). Fragment shifted bands of five target genes (hRad50, FLJ11383,
TGFRII, BAX, and ACVRII) are shown in five MSI-H colorectal carcinomas,
whereas no shifted bands were found in the three MSS colorectal carcinomas.
Figure 3. The rate of chromosomal losses and gains observed in 39 desig-
nated nonacrocentric chromosomal arms of MSI-H colorectal carcinomas (A)
and 20 MSS colorectal carcinomas (B). Each bar represents the percentage
loss (lower) or gain (upper) of a chromosomal arm.
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0.20). There was no difference in the incidence of frame-
shift mutations of the 45 target genes in MSI-H carcino-
mas with and without CIs, except for the hRAD50 and
FLJ11383 genes. Mutation of hRAD50, a member of the
DNA repair genes, was significantly related to MSI-H
colorectal carcinomas with CIs (P  0.01). Mutation of
FLJ11383, the function of which is unknown, was also
frequent in MSI-H tumors with CIs (P  0.02). There was
also a tendency toward more frequent frameshift muta-
tions of ATR and MBD4, both of which are DNA repair
genes, in MSI-H colorectal carcinomas with CIs (Table 2).
Discussion
CIs are common phenomena in human cancers, but their
causes and consequences are not well defined. Of the
two main forms of genomic instability, CIN and MSI, CIN
is known to be closely associated with CIs, and the CIN
phenotype is characterized by gross rearrangement of
chromosomes. Common CIs include the loss or gain of
whole chromosomes or chromosomal fragments, and
amplification of chromosome.23 Chromosomal loss can
lead to the inactivation of tumor suppressor genes,
whereas chromosomal gains can lead to the activation of
proto-oncogenes. The other frequent CIs involves trans-
location, which can lead to the deregulation of gene
expression or aberrant gene expression related to tumor-
igenesis by causing two genes to fuse.24 In contrast, the
MSI phenotype is characterized by small point mutations
or small deletions because of defects in the mismatch
repair genes. Recent studies have found that most of the
sporadic MSI-H carcinomas result from the inactivation of
the hMLH1 gene, principally by transcriptional silenc-
ing.25,26 In this study, we found CIs in a subset of MSI-H
colorectal carcinomas. Although it is widely accepted
that CIs are rare in MSI-H tumors, a few studies on CIs in
MSI-H carcinomas are available. The majority of previous
studies about CIs in MSI-H tumors have included a small
number of cases, and the results obtained have been
conflicting.11,12,27–29 The co-existence of two kinds of
genomic instability in several colorectal cancer cell lines
has been reported.13 In this study, we examined CIs in a
relatively large number of cases (n  39) and found CIs
in 12 (31%) cases. These findings indicate that some
colorectal carcinomas have both types of genomic insta-
bility, and therefore, it might show biological behaviors
that differ from those showing only one of the two typical
genetic instabilities.
The tumor development stage and the genetic events
that initiate CIs in MSI-H colorectal carcinomas are im-
portant for the understanding of the molecular pathogen-
esis of colorectal carcinomas. The MSI pathway begins
with the inactivation of one of a group of genes respon-
sible for DNA nucleotide mismatch repair, which leads to
extensive point mutations and frameshift mutations in
repetitive DNA sequences with low frequencies of allelic
losses and rare alterations of tumor DNA content.30 Fre-
quent somatic frameshift mutations in the genes contain-
ing nucleotide repeats in their coding sequences have
been reported,14,15,31–33 and many of these genes are
regarded as target genes in MSI-H tumors. At present,
many genes have been reported to be candidate target
genes.34 We previously proposed a role for frameshift
mutations during carcinoma transformation. We found
that the incidence and type of inactivation patterns of the
mismatch-repair genes were the same in MSI-H gastric
adenomas and carcinomas, but that frameshift mutations
were much more frequent in MSI-H gastric carcinomas.35
Table 1. Comparison of Clinical and Pathological Features of MSI-H Colorectal Carcinomas with and without CIs
Variables Categories
% of MSI-H colorectal carcinomas
P valueWith CIs (no.) Without CIs (no.)
Differentiation Well and Moderate 50 (6) 41 (11) 0.9
Poor 50 (6) 59 (16)
Site Right 67 (8) 85 (23) 0.2
Left 33 (4) 15 (4)
Age 50 33 (4) 37 (10) 1.0
50 67 (8) 63 (17)
Sex Male 50 (6) 56 (15) 1.0
Female 50 (6) 44 (12)
Peritumoral lymphoid reaction Absent 17 (2) 30 (8) 0.5
Present 83 (10) 70 (19)
Extracellular mucin formation Absent 25 (3) 48 (13) 0.3
Present 75 (9) 52 (14)
Perineural invasion Absent 92 (11) 96 (26) 0.5
Present 8 (1) 4 (1)
Extramural vessel invasion Absent 67 (8) 89 (24) 0.2
Present 33 (4) 11 (3)
TNM stage I & II 75 (9) 74 (20) 1.0
III & IV 25 (3) 26 (7)
hMLH1 expression Absent 75 (9) 81 (22) 0.7
Present 25 (3) 19 (5)
hMSH2 expression Absent 0 (0) 0 (0)
Present 100 (12) 100 (27)
hMLH1 methylation Absent 2 (17) 3 (11) 0.6
Present 10 (83) 24 (89)
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This suggests that the accumulated frameshift mutations
of the target genes are related to the malignant transfor-
mation of MSI-H tumors. The incidence of frameshift mu-
tations of the target genes in our MSI-H tumors with CIs
was slightly higher than that of the MSI-H tumors without
CIs, suggesting that the progression period of the MSI
pathway might be longer in MSI-H tumors with CIs. We
also found that chromosomal changes in MSI-H colon
carcinomas are much less frequent than changes of MSS
carcinomas and that the types of chromosomes involved
Table 2. Comparison of Frameshift Mutations of Target Genes in MSI-H Colorectal Carcinomas with and without CIs
Genes
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hRAD50 67 (8) 0 (0) 19 (5) 0 (0) 0.01 A (9) DNA double strand
breaks repair
FLJ11383 100 (12) 58 (7) 63 (17) 29 (5) 0.02 0.12 A (10) Unknown
ATR 50 (6) 0 (0) 22 (6) 0 (0) 0.13 A (10) Checkpoint kinase
MBD4 50 (6) 33 (2) 22 (6) 0 (0) 0.13 0.46 A (10) DNA glycosylase,
Methyl-CpG binding
protein
RFC3 33 (4) 0 (0) 15 (4) 0 (0) 0.22 A (10) DNA replication factor
FLJ13615 42 (5) 0 (0) 19 (5) 0 (0) 0.23 A (11) Unknown
TGFRII 100 (12) 83 (10) 81 (22) 68 (15) 0.30 0.68 A (10) Tumor suppressor
BRCA2 8 (1) 0 (0) 0 (0) 0 (0) 0.32 A (8) Tumor suppressor
FLJ11712 8 (1) 8 (1) 22 (6) 0 (0) 0.4 0.31 A (10) Unknown
PRKDC 8 (1) 0 (0) 22 (6) 0 (0) 0.4 A (10) DNA-dependent protein
kinase
ABCF1 33 (4) 0 (0) 19 (5) 0 (0) 0.42 A (10) Unknown
MARCKS 83 (10) 20 (2) 67 (18) 28 (5) 0.45 0.68 A (11) Cell proliferation and
differentiation
FLJ11186 75 (9) 0 (0) 59 (16) 4 (1) 0.48 1 A (11) Unknown
GRB-14 42 (5) 0 (0) 30 (8) 0 (0) 0.49 A (9) Growth factor bound
protein
NADH-UOB 67 (8) 0 (0) 52 (14) 0 (0) 0.49 T (9) NADH ubiquinone
oxydoreductase
Caspase 5 42 (5) 17 (1) 59 (16) 40 (6) 0.50 0.61 A (10) Apoptosis
MAC30 8 (1) 0 (0) 4 (1) 0 (0) 0.53 A (10) Unknown
BLM 25 (3) 0 (0) 15 (4) 0 (0) 0.65 A (9) DNA helicase
DKFZp564C2478 25 (3) 8 (1) 15 (4) 4 (1) 0.65 0.53 A (10) Unknown
TAF1B 92 (11) 0 (0) 81 (22) 11 (3) 0.65 0.54 A (11) Transcription factor
TCF6L1 58 (7) 0 (0) 44 (12) 0 (0) 0.65 A (10) Transcription factor
GART 25 (3) 0 (0) 19 (5) 0 (0) 0.68 A (10) Unknown
ACVRII 83 (10) 50 (5) 70 (19) 47 (9) 0.69 1 A (8) Growth factor receptor
KIAA1052 25 (3) 0 (0) 37 (10) 0 (0) 0.71 A (11) Unknown
SPINK5 25 (3) 0 (0) 37 (10) 0 (0) 0.71 A (10) Serine protease inhibitor
TCF4 75 (9) 33 (3) 63 (17) 24 (4) 0.71 0.66 A (9) Transcription factor
BAX 42 (5) 20 (1) 33 (9) 22 (2) 0.72 1 G (8) Apoptosis
UVRAG 42 (5) 0 (0) 33 (9) 0 (0) 0.72 A (10) Unknown
hMSH3 50 (6) 17 (1) 59 (16) 13 (2) 0.85 1 A (8) DNA mismatch repair
KIAA1470 50 (6) 8 (1) 41 (11) 11 (3) 0.85 1 A (10) Unknown
SEC63 58 (7) 17 (2) 56 (15) 15 (4) 0.85 1 A (10) ER membrane protein
AIM2 67 (8) 8 (1) 67 (18) 19 (5) 1 0.65 A (10) IFN inducible
BRCA1 0 (0) 0 (0) 4 (1) 0 (0) 1 A (8) Tumor suppresor
CHD2 8 (1) 8 (1) 15 (4) 0 (0) 1 0.31 A (10) Sequence-selective
DNA binding protein
FLJ11222 25 (3) 0 (0) 26 (7) 0 (0) 1 A (10) Unknown
FLJ20139 25 (3) 8 (1) 30 (8) 19 (5) 1 0.65 A (10) Unknown
FLJ20333 17 (2) 0 (0) 22 (6) 0 (0) 1 A (10) Unknown
hMSH6 17 (2) 0 (0) 26 (7) 29 (2) 1 1 C (8) DNA mismatch repair
KIAA1096 8 (1) 0 (0) 15 (4) 0 (0) 1 A (10) Unknown
KIAA1268 25 (3) 8 (1) 22 (6) 0 (0) 1 0.31 A (10) Unknown
OGT 42 (5) 8 (1) 41 (11) 11 (3) 1 1 T (10) O-linked GlcNAc
transferase
PRKWNK1 25 (3) 0 (0) 26 (7) 4 (1) 1 1 A (10) Unknown
SLC24AI 42 (5) 0 (0) 37 (10) 0 (0) 1 C (9) Nucleobase transporter
SYCP1 25 (3) 0 (0) 22 (6) 0 (0) 1 A (10) Synaptonemal complex
WISP3 8 (1) 0 (0) 15 (4) 25 (1) 1 1 A (9) Growth factor (Wnt
pathway)
* P value of total allelic mutations with and without CIs.
† P value of biallelic mutations with and without CIs.
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are quite different. These findings suggest that some
tumors following the MSI pathway can have mutations in
the genes responsible for CIN and these defects might
be selected13 during tumor progression. However, the
genetic pathways responsible for inducing CIN might
differ from that of MSS tumors.
The reported target genes of MSI-H tumors can be
functionally categorized as tumor suppressors, and
genes involved in apoptosis and DNA repair. Many
genes involved in DNA damage signaling and DNA re-
pair pathways play critical roles in the suppression of
genome instabilities. Inactivating mutations of ATM,
BRCA1, BRCA2, NBS1, and BLM genes cause defects in
DNA damage signaling and DNA repair, give rise to
some forms of CIN, and contribute to carcinogenesis.36
We and others have reported that several genes involved
in DNA repair have mononucleotide repeats in their cod-
ing sequence and are frequently mutated in MSI-H colo-
rectal carcinomas.14,15,33,37 We analyzed the relationship
between target gene mutation and CIs in MSI-H tumors,
and found that frameshift mutation of hRAD50 is signifi-
cantly related to CIs in MSI-H tumors. hRAD50 forms a
complex with hMRE11 and NBS1. The role of this hetero-
trimer in DNA damage signaling and chromosome insta-
bility has been reported.38,39 Based on the reported func-
tional characteristics of the hRAD50/MRE11/NBS1
complex, our findings indicate that CIN in MSI-H colorec-
tal carcinomas might be induced from the functional al-
terations of hRAD50.
We cannot explain the significance of the high fre-
quency of mutations of FLJ11383 in MSI-H tumors with
CIs, because the functionality of FLJ11383 is unknown. In
addition to hRAD50 and FLJ11383, mutations of the other
genes involved in DNA repair, ATR and MBD4, also
showed trends toward more frequent mutations in MSI-H
tumors with CIs. Future analysis of a larger series of
cases and the determination of the functional mechanism
of the CIN of these genes should clarify the associations
between mutations of these genes and genetic progres-
sion via the CIN pathway in MSI-H carcinomas.
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